TFRC and leukemia: In this case, the surface of the loaded nanoparticles can befunctionalized with targeted antibodies to enhance the directed accumulation ofparticles in the tumor, which was demonstrated in breast tumors via targetingof the transferrin receptor CD71 [72];pancreatic cancer cells via targeting of the gastrin receptor [72]; and leukemia cells via targeting of thereceptor tyrosine kinase CD117 and type I transmembrane glycoprotein CD96[73].